ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
Sep 23, 2024 · Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and increased the rates of disability improvement compared with a placebo in people with nonrelapsing...
Press Room - Sanofi US News
Sep 20, 2024 · The significant impact of tolebrutinib on disability accumulation versus teriflunomide, in the absence of a statistically superior impact on relapses, suggests that tolebrutinib may address smoldering neuroinflammation, which manifests as progression independent of relapses.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Nov 5, 2024 · Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French...
Press Room - Sanofi US News
Feb 24, 2022 · New preclinical data demonstrated that tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), was the only BTK inhibitor with sufficient central nervous system (CNS) exposure and potency to modulate BTK signaling pathways within the CNS, as compared with evobrutinib ...
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT
Sep 2, 2024 · Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies,...
Tolebrutinib Shows Positive Results in Slowing Disability …
Sep 20, 2024 · In a phase 3 study, tolebrutinib demonstrated a statistically significant delay in time to onset of confirmed disability progression in patients living with non-relapsing secondary progressive multiple sclerosis.
Feb 23, 2023 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
Sep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis.
Results From Tolebrutinib Studies | National MS Society
Sep 3, 2024 · Sanofi announced that Tolebrutinib – an experimental, oral BTK-inhibitor – met the primary endpoint of delaying time to onset of confirmed disability progression in the HERCULES study among people with non-relapsing secondary progressive multiple sclerosis.*
- Some results have been removed